Clinicopathological analysis of 7 cases of non-small cell lung cancer with co-expression of P40 and TTF-1
Objective:P40 and thyroid transcription factor-1(TTF-1)are widely used in the differential diagnosis of lung squamous cell carcinoma and lung adenocarcinoma.However,co-expression of both markers in non-small cell lung cancer(NSCLC)cases is extremely rare.This study aims to investigate the clinical and pathological characteristics of NSCLC with co-expression of P40 and TTF-1.Methods:Seven cases of NSCLC with co-expression of P40 and TTF-1 diagnosed from May 2019 to September 2023 at Weihai Municipal Hospital affiliated to Shandong University were collected.Clinical and pathological characteristics were analyzed.Gene detection and immunohistochemical testing of relevant markers were performed,and patient follow-up was conducted.Results:All 7 patients were male,aged 57 to 80(median 71)years.Except for one patient,all others had a history of smoking.Six patients had peripheral tumors and one had a central type,with tumor sizes ranging from 2.0 to 8.5(median 5.8)cm.Five patients had tumor metastasis.The two deceased patients survived for 12 and 55 months from initial diagnosis to death,respectively.The tumors showed poor differentiation,dense arrangement of tumor cells with patchy and nest-like distribution,and inflammatory cell infiltration by HE staining.Tumor cells varied in size and shape,with eosinophilic cytoplasm and irregularly shaped nuclei with visible nucleoli.Immunohistochemical staining showed widespread positive for P40,TTF-1,P63,cytokeratin(CK)7,and CK5/6,while Napsin A was mostly negative.Gene testing revealed TP53 mutation in one case and no mutations in the others.Conclusion:Co-expression of P40 and TTF-1 in NSCLC is a rare subtype with low incidence but high malignancy,predominantly affecting elderly individuals with a history of smoking.Most cases are diagnosed at an advanced stage,and pathological results show poorly differentiated tumors that do not belong to adenocarcinoma or squamous cell carcinoma.
万方数据
维普
